[1] Zhou MG, Wang HD, Zeng XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990−2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019; 394, 1145−58.
[2] Chinese Center for Disease Control and Prevention, Wang XH. Chinese adult tobacco survey in 2018. People’s Medical Publishing House Co. , LTD. 2020. (In Chinese)
[3] Pang YJ, Yu CQ, Guo Y, et al. Associations of lifestyles with major chronic diseases in Chinese adults: evidence from the China Kadoorie Biobank. Chin J Epidemiol, 2021; 42, 369−75. (In Chinese
[4] Yu DM, Zhao LY, Ju LH, et al. Status of energy and primary nutrients intake among Chinese population in 2015-2017. Food Nutr China, 2021; 27, 5−10. (In Chinese
[5] Piao W, Yu DM, Ju LH, et al. Intakes of energy and macronutrients in 6-11 years old age group in 2016-2017 in China. J Hyg Res, 2021; 50, 389−94. (In Chinese
[6] Ju LH, Zhao LY, Fang HY, et al. The status of energy and macronutrients intake among children of 12–17 years old in China from 2016 to 2017. Food Nutr China, 2021; 27, 20−5. (In Chinese
[7] Zhang JG, Wang ZH, Du WW, et al. Twenty-five-year trends in dietary patterns among Chinese adults from 1991 to 2015. Nutrients, 2021; 13, 1327. doi:  10.3390/nu13041327
[8] Liu SN, Zhang TW, Pan F, et al. Analysis on sugar intake from carbonated beverages aged 3 years and above of China. Chin J Food Hyg, 2020; 32, 556−60. (In Chinese
[9] Bi XY, Li L, Yang TT, et al. Snack consumption and the influencing factors of students participation in the nutrition improvement program for rural compulsory education in 2019. Chin J Sch Health, 2021; 42, 329−33. (In Chinese
[10] Ju LH, Yu DM, Guo QY, et al. Eating out behavior and its impact on obesity among Chinese residents aged 18–59 in 2015. J Hyg Res, 2021; 50, 395−400. (In Chinese
[11] Yao YC, Gong WY, Song C, et al. Out-of-home eating behavior analysis of Chinese adult residents, 2010-2012. Acta Nutr Sin, 2019; 41, 10−4. (In Chinese
[12] Piao W, Zhao LY, Fang HY, et al. Status of drinking behaviors in adults aged 18 years old and over in China. Food Nutr China, 2021; 27, 15−9. (In Chinese
[13] Liu M, Wang CR, Liang JJ, et al. Change trend in disease burden of stroke and its risk factors in China, 1990–2017. Chin J Public Health, 2021; 37, 1501−7. (In Chinese
[14] Han YT, Hu YZ, Yu CQ, et al. Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study. Eur Heart J, 2021; 42, 3374−84. doi:  10.1093/eurheartj/ehab413
[15] Neal B, Wu YF, Feng XX, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med, 2021; 385, 1067−7. doi:  10.1056/NEJMoa2105675
[16] Strain T, Brage S, Sharp SJ, et al. Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity: a descriptive study. Lancet Glob Health, 2020; 8, e920−30. doi:  10.1016/S2214-109X(20)30211-4
[17] Cao JH, Eshak ES, Liu KY, et al. An age-period-cohort analysis of stroke mortality attributable to low physical activity in China and Japan: data from the GBD study 1990–2016. Sci Rep, 2020; 10, 6525. doi:  10.1038/s41598-020-63307-x
[18] Liu Q, Liu FC, Huang KY, et al. Beneficial effects of moderate to vigorous physical activity on cardiovascular disease among Chinese adults. J Geriatr Cardiol, 2020; 17, 85−95.
[19] Bennett DA, Du HD, Clarke R, et al. Association of physical activity with risk of major cardiovascular diseases in Chinese men and women. JAMA Cardiol, 2017; 2, 1349−58. doi:  10.1001/jamacardio.2017.4069
[20] Liu Y, Wen WQ, Gao YT, et al. Level of moderate-intensity leisure-time physical activity and reduced mortality in middle-aged and elderly Chinese. J Epidemiol Community Health, 2018; 72, 13−20. doi:  10.1136/jech-2017-209903
[21] Pan XF, Wang LM, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol, 2021; 9, 373−92. doi:  10.1016/S2213-8587(21)00045-0
[22] Mu L, Liu JM, Zhou GH, et al. Obesity prevalence and risks among Chinese adults: findings from the China PEACE million persons project, 2014-2018. Circ Cardiovasc Qual Outcomes, 2021; 14, e007292. doi:  10.1161/CIRCOUTCOMES.120.007292
[23] Wang YF, Zhao L, Gao LW, et al. Health policy and public health implications of obesity in China. Lancet Diabetes Endocrinol, 2021; 9, 446−61. doi:  10.1016/S2213-8587(21)00118-2
[24] Chen Z, Jiang S, Wang YF, et al. Pharmacoeconomics of obesity in China: a scoping review. Expert Rev Pharmacoecon Outcomes Res, 2021; 21, 173−81. doi:  10.1080/14737167.2021.1882306
[25] Zhao DM, Wu ZG, Zhang HF, et al. Somatic symptoms vary in major depressive disorder in China. Compr Psychiatry, 2018; 87, 32−7. doi:  10.1016/j.comppsych.2018.08.013
[26] Wang ZW, Chen Z, Zhang LF, et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation, 2018; 137, 2344−56. doi:  10.1161/CIRCULATIONAHA.117.032380
[27] Zhang M, Wu J, Zhang X, et al. Prevalence and control of hypertension in adults in China, 2018. Chin J Epidemiol, 2021; 42, 1780−89. (In Chinese
[28] Luo YM, Xia F, Yu XX, et al. Long-term trends and regional variations of hypertension incidence in China: a prospective cohort study from the China health and nutrition survey, 1991-2015. BMJ Open, 2021; 11, e042053. doi:  10.1136/bmjopen-2020-042053
[29] Zhang WL, Zhang SY, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med, 2021; 385, 1268−79. doi:  10.1056/NEJMoa2111437
[30] Xie XL, He TH, Kang J, et al. Cost-effectiveness analysis of intensive hypertension control in China. Prev Med, 2018; 111, 110−4. doi:  10.1016/j.ypmed.2018.02.033
[31] Wang ZW, Hao G, Wang X, et al. Clinical outcomes and economic impact of the 2017 ACC/AHA guidelines on hypertension in China. J Clin Hypertens (Greenwich), 2019; 21, 1212−20. doi:  10.1111/jch.13609
[32] Zhang SY, Tao LY, Yang YY, et al. Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drugs treatment: a multicenter prospective study in China. Chin Med J (Engl), 2021; 134, 292−301. doi:  10.1097/CM9.0000000000001360
[33] Dong J, Dong HB, Yan YK, et al. Prevalence of hypertension and hypertension phenotypes after three visits in Chinese urban children. J Hypertens, 2022; 40, 1270−7.
[34] Xu HQ, Li YP, Shang XW, et al. Effect of comprehensive interventions including nutrition education and physical activity on high blood pressure among children: evidence from school-based cluster randomized control trial in China. Int J Environ Res Public Health, 2020; 17, 8944. doi:  10.3390/ijerph17238944
[35] Song PK, Man QQ, Li H, et al. Trends in lipids level and dyslipidemia among Chinese adults, 2002-2015. Biomed Environ Sci, 2019; 32, 559−70.
[36] NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature, 2020; 582, 73−7. doi:  10.1038/s41586-020-2338-1
[37] Pan L, Yang ZH, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 2016; 248, 2−9. doi:  10.1016/j.atherosclerosis.2016.02.006
[38] Dai J, Min JQ, Yang YJ. A study on the epidemic characteristics of dyslipidemia in adults of nine provinces of China. Chin J Cardiol, 2018; 46, 114−8. (In Chinese
[39] Li SN, Zhang LF, Wang X, et al. Status of dyslipidemia among adults aged 35 years and above in China. Chin Circ J, 2019; 34, 681−7. (In Chinese
[40] Opoku S, Gan Y, Fu WN, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China national stroke screening and prevention project (CNSSPP). BMC Public Health, 2019; 19, 1500. doi:  10.1186/s12889-019-7827-5
[41] Zhang M, Deng Q, Wang LH, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163, 641 adults. Int J Cardiol, 2018; 260, 196−203. doi:  10.1016/j.ijcard.2017.12.069
[42] Wang ZH, Zou ZY, Yang YD, et al. The epidemiological characteristics and related factors of dyslipidemia among children and adolescents aged 6-17 years from 7 provinces in China, 2012. Chin J Prev Med, 2018; 52, 798−801. (In Chinese
[43] Zhao W, Ye P, Hu DY, et al. Re-analysis of DYSIS-China cross-sectional survey according to "Chinese guidelines for the prevention and treatment of dyslipidemia in adults (2016 revision)". Chin J Cardiovasc Med, 2020; 25, 55−61. (In Chinese
[44] Xing YY, Liu J, Hao YC, et al. Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: findings from the improving care for cardiovascular disease in China (CCC) project. Am Heart J, 2019; 212, 120−8. doi:  10.1016/j.ahj.2019.02.019
[45] Xing YY, Liu J, Liu J, et al. Statin use and low-density lipoprotein cholesterol levels in patients aged 75 years and older with acute coronary syndrome in China. Chin J Cardiol, 2019; 47, 351−9. (In Chinese
[46] Xu XH, Yang J, Wang LJ, et al. Burden of disease attributed to high level serum low-density lipoprotein cholesterol in China in 2017. Chin J Epidemiol, 2020; 41, 839−44. (In Chinese
[47] Song YJ, Du X, Zheng MY, et al. A prospective cohort study of the effect of cumulative exposure to low-density lipoprotein cholesterol on new-onset acute myocardial infarction. Chin Circ J, 2020; 35, 246−53. (In Chinese
[48] Sun LL, Clarke R, Bennett D, et al. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nat Med, 2019; 25, 569−74. doi:  10.1038/s41591-019-0366-x
[49] Wang M, Liu J, Bellows BK, et al. Impact of China's low centralized medicine procurement prices on the cost-effectiveness of statins for the primary prevention of atherosclerotic cardiovascular disease. Glob Heart, 2020; 15, 43. doi:  10.5334/gh.830
[50] Li YZ, Teng D, Shi XG, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American diabetes association: national cross sectional study. BMJ, 2020; 369, m997.
[51] Wang M, Gong WW, Pan J, et al. Incidence and time trends of type 2 diabetes mellitus among adults in Zhejiang Province, China, 2007-2017. J Diabetes Res, 2020; 2020, 2597953.
[52] Gong QH, Zhang P, Wang JP, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing diabetes prevention outcome study. Lancet Diabetes Endocrinol, 2019; 7, 452−61. doi:  10.1016/S2213-8587(19)30093-2
[53] Ma J, Wan X, Wu B. The cost-effectiveness of lifestyle interventions for preventing diabetes in a health resource-limited setting. J Diabetes Res, 2020; 2020, 7410797.
[54] Jin HY, Zhou JY, Wu CK. Prevalence and health correlates of reduced kidney function among community-dwelling Chinese older adults: the China health and retirement longitudinal study. BMJ Open, 2020; 10, e042396. doi:  10.1136/bmjopen-2020-042396
[55] Zhang LX, Zhao MH, Zuo L, et al. China kidney disease network (CK-NET) 2016 annual data report. Kidney Int Suppl (2011), 2020; 10, e97−185. doi:  10.1016/j.kisu.2020.09.001
[56] Li YR, Zhao LY, Yu DM, et al. Metabolic syndrome prevalence and its risk factors among adults in China: A nationally representative cross-sectional study. PLoS One, 2018; 13, e0199293. doi:  10.1016/j.ijcard.2018.04.100
[57] Liang FC, Xiao QY, Huang KY, et al. The 17-y spatiotemporal trend of PM2.5 and its mortality burden in China. Proc Natl Acad Sci USA, 2020; 117, 25601−8. doi:  10.1073/pnas.1919641117
[58] Liu C, Yin P, Chen RJ, et al. Ambient carbon monoxide and cardiovascular mortality: a nationwide time-series analysis in 272 cities in China. Lancet Planet Health, 2018; 2, e12−8. doi:  10.1016/S2542-5196(17)30181-X
[59] Chen RJ, Yin P, Meng X, et al. Fine particulate air pollution and daily mortality. A nationwide analysis in 272 Chinese cities. Am J Respir Crit Care Med, 2017; 196, 73−81. doi:  10.1164/rccm.201609-1862OC
[60] Chen RJ, Yin P, Meng X, et al. Associations between ambient nitrogen dioxide and daily cause-specific mortality: evidence from 272 Chinese cities. Epidemiology, 2018; 29, 482−9. doi:  10.1097/EDE.0000000000000829
[61] Chen RJ, Yin P, Meng X, et al. Associations between coarse particulate matter air pollution and cause-specific mortality: a nationwide analysis in 272 Chinese cities. Environ Health Perspect, 2019; 127, 017008. doi:  10.1289/EHP2711
[62] Yu K, Lv J, Qiu GK, et al. Cooking fuels and risk of all-cause and cardiopulmonary mortality in urban China: a prospective cohort study. Lancet Glob Health, 2020; 8, e430−9. doi:  10.1016/S2214-109X(19)30525-X
[63] Hou L, Chen B, Ji YB, et al. China CDC in action - hypertension prevention and control. China CDC Wkly, 2020; 2, 783−6. doi:  10.46234/ccdcw2020.212
[64] National Health Commission of the People’s Republic of China. China health statistical yearbook 2020. Peking Union Medical College Press. 2020. (In Chinese)
[65] Zhong Q, Gao Y, Zheng X, et al. Geographic variation in process and outcomes of care for patients with acute myocardial infarction in China from 2001 to 2015. JAMA Netw Open, 2020; 3, e2021182. doi:  10.1001/jamanetworkopen.2020.21182
[66] Xu HY, Yang YJ, Wang CS, et al. Association of hospital-level differences in care with outcomes among patients with acute ST-segment elevation myocardial infarction in China. JAMA Netw Open, 2020; 3, e2021677. doi:  10.1001/jamanetworkopen.2020.21677
[67] Atkins ER, Du X, Wu YF, et al. Use of cardiovascular prevention treatments after acute coronary syndrome in China and associated factors. Int J Cardiol, 2017; 241, 444−9. doi:  10.1016/j.ijcard.2017.03.057
[68] Li J, Dharmarajan K, Bai XK, et al. Thirty-day hospital readmission after acute myocardial infarction in China. Circ Cardiovasc Qual Outcomes, 2019; 12, e005628. doi:  10.1161/CIRCOUTCOMES.119.005628
[69] Song JL, Murugiah K, Hu S, et al. Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction in China. Heart, 2021; 107, 313−8. doi:  10.1136/heartjnl-2020-317165
[70] Zhao YY, Yang JG, Xu HB, et al. Association between the composite measures of hospital performance and in-hospital mortality for patients with acute ST-segment elevation myocardial infarction in China. Chin Circ J, 2019; 34, 437−43. (In Chinese
[71] National Center for Cardiovascular Quality Improvement. 2021 Medical quality report of cardiovascular diseases in China: an executive summary. Chin Circ J, 2021; 36, 1041−64. (In Chinese
[72] Hu Z, Chen SP, Du JZ, et al. An in-hospital mortality risk model for patients undergoing coronary artery bypass grafting in China. Ann Thorac Surg, 2020; 109, 1234−42. doi:  10.1016/j.athoracsur.2019.08.020
[73] Lin S, Li ZG, Fu BW, et al. Feasibility of using deep learning to detect coronary artery disease based on facial photo. Eur Heart J, 2020; 41, 4400−11. doi:  10.1093/eurheartj/ehaa640
[74] GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol, 2021; 20, 795−820. doi:  10.1016/S1474-4422(21)00252-0
[75] Xia F, Yu XX, Li YK, et al. Geographic variations of stroke incidence in Chinese communities: an 18-year prospective cohort study from 1997 to 2015. J Stroke, 2020; 22, 345−56. doi:  10.5853/jos.2020.02383
[76] Jiang B, Sun HX, Ru XJ, et al. Prevalence, incidence, prognosis, early stroke risk, and stroke-related prognostic factors of definite or probable transient ischemic attacks in China, 2013. Front Neurol, 2017; 8, 309. doi:  10.3389/fneur.2017.00309
[77] Wang WZ, Jiang B, Sun HX, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation, 2017; 135, 759−71. doi:  10.1161/CIRCULATIONAHA.116.025250
[78] Gu M, Hu YR, Hua W, et al. Visualization of tricuspid valve annulus for implantation of His bundle pacing in patients with symptomatic bradycardia. J Cardiovasc Electrophysiol, 2019; 30, 2164−9. doi:  10.1111/jce.14140
[79] Wang ZW, Chen Z, Wang X, et al. The disease burden of atrial fibrillation in China from a national cross-sectional survey. Am J Cardiol, 2018; 122, 793−8. doi:  10.1016/j.amjcard.2018.05.015
[80] Guo J, Guan TJ, Fan SY, et al. Underuse of oral anticoagulants in patients with ischemic stroke and atrial fibrillation in China. Am J Cardiol, 2018; 122, 2055−61. doi:  10.1016/j.amjcard.2018.08.057
[81] Liu Y, Zhan XZ, Xue YM, et al. Incidence and outcomes of cerebrovascular events complicating catheter ablation for atrial fibrillation. Europace, 2016; 18, 1357−65. doi:  10.1093/europace/euv356
[82] Ge HY, Li XM, Jiang H, et al. Clinical characteristics and treatment of congenital long QT syndrome in 58 chiLdren. Chin J Pediatr, 2019; 57, 272−6. (In Chinese
[83] Jia PL, Wang YB, Fu H, et al. Postmortem analysis of 4 mutation hotspots of KCNQ1, KCNH2, and SCN5A genes in sudden unexplained death in southwest of China. Am J Forensic Med Pathol, 2018; 39, 218−22. doi:  10.1097/PAF.0000000000000411
[84] Yang Y, Wang ZW, Chen Z, et al. Current status and etiology of valvular heart disease in China: a population-based survey. BMC Cardiovasc Disord, 2021; 21, 339. doi:  10.1186/s12872-021-02154-8
[85] Wang YS, Wu BT, Li J, et al. Distribution patterns of valvular and vascular complications in bicuspid aortic valve. Int Heart J, 2020; 61, 273−80. doi:  10.1536/ihj.19-467
[86] Zhao LJ, Chen LZ, Yang TB, et al. Birth prevalence of congenital heart disease in China, 1980-2019: a systematic review and meta-analysis of 617 studies. Eur J Epidemiol, 2020; 35, 631−42. doi:  10.1007/s10654-020-00653-0
[87] Zhao QM, Liu F, Wu L, et al. Prevalence of congenital heart disease at live birth in China. J Pediatr, 2019; 204, 53−8. doi:  10.1016/j.jpeds.2018.08.040
[88] Chinese Society of Extracorporeal Circulation. White book of Chinese cardiovascular surgery and extracorporeal circulation in 2020. Chin J Extracorpor Circ, 2021; 19, 257−60. (In Chinese
[89] Cooperation Group of Precision Diagnosis and Treatment of Cardiomyopathy in Children, the Subspecialty Group of Cardiology, the Society of Pediatrics, Chinese Medical Association. Investigation and analysis of cardiomyopathy in children from 33 hospitals in China: a multicenter study of 4 981 cases from 2006 to 2018. Chin J Appl Clin Pediatr, 2021; 36, 983−9. (In Chinese
[90] Wu GX, Liu LW, Zhou ZY, et al. East Asian-specific common variant in TNNI3 predisposes to hypertrophic cardiomyopathy. Circulation, 2020; 142, 2086−9. doi:  10.1161/CIRCULATIONAHA.120.050384
[91] Christensen AH, Platonov PG, Jensen HK, et al. Genotype-phenotype correlation in arrhythmogenic right ventricular cardiomyopathy-risk of arrhythmias and heart failure. J Med Genet, 2021.
[92] Chen L, Rao M, Chen X, et al. A founder homozygous DSG2 variant in east Asia results in ARVC with full penetrance and heart failure phenotype. Int J Cardiol, 2019; 274, 263−70. doi:  10.1016/j.ijcard.2018.06.105
[93] Rao M, Guo GR, Li MM, et al. The homozygous variant c. 245G > A/p. G82D in PNPLA2 is associated with arrhythmogenic cardiomyopathy phenotypic manifestations. Clin Genet, 2019; 96, 532−40. doi:  10.1111/cge.13642
[94] Sun HR, Hao XY, Wang X, et al. Genetics and clinical features of noncompaction cardiomyopathy in the fetal population. Front Cardiovasc Med, 2020; 7, 617561.
[95] Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China hypertension survey, 2012-2015. Eur J Heart Fail, 2019; 21, 1329−37. doi:  10.1002/ejhf.1629
[96] Zhang YH, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) registry. J Card Fail, 2017; 23, 868−75. doi:  10.1016/j.cardfail.2017.09.014
[97] Working Group on Heart Failure, National Center for Cardiovascular Quality Improvement (NCCQI). 2020 Clinical performance and quality measures for heart failure in China. Chin Circ J, 2021; 36, 221−38. (In Chinese
[98] Li Y, Sun XL, Qiu H, et al. Long-term outcomes and independent predictors of mortality in patients presenting to emergency departments with acute heart failure in Beijing: a multicenter cohort study with a 5-year follow-up. Chin Med J (Engl), 2021; 134, 1803−11. doi:  10.1097/CM9.0000000000001617
[99] Li M, Wang Q, Zhao J, et al. Chinese SLE treatment and research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus, 2014; 23, 1085−91. doi:  10.1177/0961203314527366
[100] Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest, 2011; 140, 301−9. doi:  10.1378/chest.10-2327
[101] Zhang Z, Lei JP, Shao X, et al. Trends in hospitalization and in-hospital mortality from VTE, 2007 to 2016, in China. Chest, 2019; 155, 342−53. doi:  10.1016/j.chest.2018.10.040
[102] Zhai ZG, Wang DY, Lei JP, et al. Trends in risk stratification, in-hospital management and mortality of patients with acute pulmonary embolism: an analysis from the China pulmonary thromboembolism registry study (CURES). Eur Respir J, 2021; 58, 2002963. doi:  10.1183/13993003.02963-2020
[103] Zhai ZG, Kan QC, Li WM, et al. VTE risk profiles and prophylaxis in medical and surgical inpatients: the identification of Chinese hospitalized patients' risk profile for venous thromboembolism (DissolVE-2)-a cross-sectional study. Chest, 2019; 155, 114−22. doi:  10.1016/j.chest.2018.09.020
[104] Xia L, Li JH, Zhao K, et al. Incidence and in-hospital mortality of acute aortic dissection in China: analysis of China health insurance research (CHIRA) data 2011. J Geriatr Cardiol, 2015; 12, 502−6.
[105] Li K, Zhang KW, Li TX, et al. Primary results of abdominal aortic aneurysm screening in the at-risk residents in middle China. BMC Cardiovasc Disord, 2018; 18, 60. doi:  10.1186/s12872-018-0793-5
[106] Jiang B, Li XT, Zhang DM, et al. Preliminary results of ultrasound screening program for abdominal aortic aneurysm in Liaoning Province, Northeast China. Chin J Vasc Surg, 2019; 4, 20−4. (In Chinese
[107] Huang TT, Liu S, Huang JH, et al. Meta-analysis of the growth rates of abdominal aortic aneurysm in the Chinese population. BMC Cardiovasc Disord, 2019; 19, 204. doi:  10.1186/s12872-019-1160-x
[108] Wang ZW, Wang X, Hao G, et al. A national study of the prevalence and risk factors associated with peripheral arterial disease from China: the China hypertension survey, 2012-2015. Int J Cardiol, 2019; 275, 165−70. doi:  10.1016/j.ijcard.2018.10.047
[109] Hua Y, Jia LY, Xing YQ, et al. Distribution pattern of atherosclerotic stenosis in Chinese patients with stroke: a multicenter registry study. Aging Dis, 2019; 10, 62−70. doi:  10.14336/AD.2018.0602
[110] Report on Stroke Prevention and Treatment in China Writing Group. Brief report on stroke prevention and treatment in China, 2019. Chin J Cerebrovasc Dis, 2020; 17, 272−81. (In Chinese
[111] Xiong HL, Peng M, Jiang XJ, et al. Time trends regarding the etiology of renal artery stenosis: 18 years' experience from the China center for cardiovascular disease. J Clin Hypertens (Greenwich), 2018; 20, 1302−9. doi:  10.1111/jch.13356
[112] Che WQ, Jiang XJ, Dong H, et al. Etiology and anatomic characteristics of subclavian artery stenosis: analysis of data from 1793 patients hospitalized in Fuwai hospital between 1999 and 2017. Chin Circ J 2018; 33, 1197-202. (In Chinese)
[113] Liu D, Ma ZQ, Yang JG, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging (Albany NY), 2019; 11, 7948−60.
[114] Zhang ZX, Pack Q, Squires RW, et al. Availability and characteristics of cardiac rehabilitation programmes in China. Heart Asia, 2016; 8, 9−12. doi:  10.1136/heartasia-2016-010758
[115] Li JN, Li LSW. Development of rehabilitation in China. Phys Med Rehabil Clin N Am, 2019; 30, 769−73. doi:  10.1016/j.pmr.2019.07.010
[116] Zhang N, Zhang YMF, Liu JY, et al. National rehabilitation medicine professional medical services and quality safety report 2019. Chin J Phys Med Rehabil, 2020; 42, 1146−52. (In Chinese
[117] Zhang YMF, Fan J, Zhou MW, et al. National report on medical services and quality safety of inpatients in rehabilitation medicine departments of tertiary hospitals, 2013-2018: based on data from the first page of hospital quality monitoring system cases. Chin J Rehabil Med, 2020; 35, 771−4. (In Chinese
[118] National Center for Cardiovascular Diseases, China. Annual report on cardiovascular health and diseases in China (2021). Science Press. 2022. (In Chinese)